摘要
目的:探讨抗甲状腺球蛋白抗体(Tg Ab)评价分化型甲状腺癌(DTC)术后131Ⅰ治疗疗效及预后的临床价值。方法:对血清甲状腺球蛋白(Tg)阴性、Tg Ab阳性且行二次131Ⅰ治疗的25例DTC转移患者进行回顾性分析,研究其131Ⅰ治疗前、治疗后6个月、治疗后1年Tg Ab水平的变化及病情发展趋势。结果:25例DTC转移患者131Ⅰ治疗不同随访时间,Tg Ab水平不同,三者差异显著(统计值:20.582,P=0.000)。治疗前水平最高,治疗后1年水平最低。有效组和无效组患者131Ⅰ治疗前Tg Ab水平差异无统计学意义(U=53.500,P=0.406);131Ⅰ治疗后1年Tg Ab水平差异显著(U=8.000,P=0.000)。治疗后有效组Tg Ab水平明显低于无效组。结论:血清Tg阴性时,Tg Ab水平可作为DTC转移患者131Ⅰ治疗疗效及预后的监测指标。
Objective：To assess the clinical value of antithyroglobulin antibodies （TgAb） in differentiated thyroid carcinoma（ DTC ） after 131 Iodine treatment. Methods：All 25 cases of Tg negative and TgAb positive with second 131 Iodine treatment were analyzed retrospectively. All of them were studied before 131 Iodine treatment and 6 months, 1 year after treatment to compare the variation of TgAb value and its tendency. Results： Twenty five patients with DTC transfer after 131 Iodine treatment at different follow - up time had different TgAb value. There was difference（P = 0.000）. The TgAb value reached the highest before treatment and the lowest one year later. Tthe TgAb level before 131 Iodine therapy of effective and ineffective group were not statistical different （ P = 0. 406 ）, but it had significant differences one year later with 131 Iodine treatment （P = 0. 000）. Meanwhile, effective group of TgAb levels after treat- ment was much lower than invalid group. Conclusion：When serum Tg is negative, TgAb can be used as the monito- ring index of DTC patients after 131 Iodine treatment.
出处
《现代肿瘤医学》
CAS
2015年第12期1659-1661,共3页
Journal of Modern Oncology
